Processa Pharmaceuticals, Inc. — Director's Dealing 2024

Apr 12, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2024-01-01

Reporting Person: Stanker James H (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-01	Common Stock	M	1675	—	Acquired	6638	Direct
2024-01-01	Common Stock	F	518	$2.79	Disposed	6120	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-01	Restricted Stock Units	$0	M	1675	Disposed		Common Stock (1675)	Direct

Footnotes

F1: Distribution of vested restricted shares.

F2: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.